Dr. Luke John Benvenuto, MD

Dr. Benvenuto practices at Trustees of Columbia University in the City of New York in New York, New York.

Dr. Benvenuto's NPI, 1417274408, was assigned on April 29, 2010. Dr. Benvenuto graduated from Icahn School Of Medicine At Mount Sinai in 2010. Dr. Benvenuto holds New York license 269140.

Dr. Benvenuto's primary practice is Trustees of Columbia University in the City of New York, at 630 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 342-5155.

Dr. Benvenuto's primary practice is Trustees of Columbia University in the City of New York in New York, New York. Dr. Benvenuto is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Benvenuto to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Benvenuto practices, 3 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Benvenuto's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Benvenuto is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Benvenuto's licenses on file in 2 states: New York and Connecticut.

Dmand AI lists chronic lung disease, chronic obstructive pulmonary disease (COPD), pneumonia, pulmonary fibrosis and pulmonary heart disease among the conditions Dr. Benvenuto treats.

CMS data shows 898 Medicare services from Dr. Benvenuto across 9 procedure codes in 2024, for 146 Medicare patients. Medicare paid $116,923 for them.

CMS counts 146 Medicare patients who saw Dr. Benvenuto in 2024. The largest group is 65 to 74, with 84 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 3.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Benvenuto's median patient age at 68, with 44% women.

In 2024, Dr. Benvenuto wrote 212 Medicare Part D claims for 55 patients. 92% of them were for generic drugs. CMS names the drug for 71 of them, across 4 drugs with 11 or more claims each, at $1,201 in total drug cost. In 2023, CMS named 89 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Benvenuto for performance year 2024, reported through an alternative payment model (APM). Dr. Benvenuto accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Benvenuto as offering telehealth.

Dmand AI links 59 papers to Dr. Benvenuto, published from 2006 to 2025. 2021 was the busiest year, with 15. The most frequent topics are Lung Transplantation, Lung and Transplant Recipients. Dr. Benvenuto has published most often in J Heart Lung Transplant. Dr. Benvenuto's most frequent co-authors are Selim Mehmet Arcasoy, MD, Frank D'Ovidio, MD and Joshua Robert Sonett.

Dmand AI links Dr. Benvenuto to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Rejection, Psychology and Social Behavior.

CMS Open Payments shows 3 general payments to Dr. Benvenuto from 2 drug and device companies from 2018 to 2019. Food and beverage make up the largest share, 100% of the total. Genentech, Inc. paid the most, $39.

Dr. Benvenuto graduated from Icahn School Of Medicine At Mount Sinai in 2010.

Dr. Benvenuto is in network with 16 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.